US Drug Recall Register

FDA Drug Recalls

17,898 recalls, newest first

Class II · Moderate risk Ongoing

Entecavir Tablets

Reason Failed Impurity/Degradation Specifications

Zydus Pharmaceuticals (USA) Inc NDC 68382-921-06 D-0657-2025
Class II · Moderate risk Ongoing

Entecavir Tablets

Reason Failed Impurity/Degradation Specifications

Zydus Pharmaceuticals (USA) Inc NDC 68382-920-06 D-0656-2025
Class II · Moderate risk Ongoing

Kit for the Preparation of Technetium Tc 99m Mertiatide

Reason Failed Dissolution Specifications-Out of Specification (OOS) observation for sulphate in Sodium Tartrate Dihydrate used for the production of Mertiatide.

Sun Pharmaceutical Industries INC NDC 45567-0655-1 D-0658-2025
Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0639-2025
Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0638-2025
Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0637-2025
Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0636-2025
Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0635-2025
Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0634-2025
Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0633-2025
Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0632-2025
Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0631-2025
Class II · Moderate risk Ongoing

Chlorpromazine Hydrochloride Tablets

Reason CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc D-0630-2025
Class II · Moderate risk Ongoing

Viorele

Reason Failed Impurities/Degradation Specifications

Glenmark Pharmaceuticals Inc., USA NDC 68462-318-29 D-0021-2026
Class II · Moderate risk Ongoing

Sulfamethoxazole and Trimethoprim

Reason Presence of a Foreign Substance: A specific lot of auxiliary polyester coil, used in product packaging by manufacturer (Amneal Pharmaceuticals LLC) was detected with presence of a micro-organism. No micro-organism was detected on any tablets.

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 55154-7895-0 D-0625-2025
Class II · Moderate risk Ongoing

Sulfamethoxazole and Trimethoprim

Reason Presence of a Foreign Substance: A specific lot of auxiliary polyester coil, used in product packaging by manufacturer (Amneal Pharmaceuticals LLC) was detected with presence of a micro-organism. No micro-organism was detected on any tablets.

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-2725-61 D-0624-2025
Class II · Moderate risk Ongoing

bevacizumab

Reason Lack of Assurance of Sterility

Fagron Compounding Services D-0646-2025
Class III · Low risk Ongoing

Dextroamphetamine Saccharate

Reason Failed Impurities/Degradation Specifications:

Granules Pharmaceuticals Inc. NDC 70010-034-01 D-0673-2025
Class III · Low risk Ongoing

Dextroamphetamine Saccharate

Reason Failed Impurities/Degradation Specifications:

Granules Pharmaceuticals Inc. NDC 70010-032-01 D-0672-2025
Class III · Low risk Ongoing

Dextroamphetamine Saccharate

Reason Failed Impurities/Degradation Specifications:

Granules Pharmaceuticals Inc. NDC 70010-031-01 D-0671-2025
Class III · Low risk Ongoing

Dextroamphetamine Saccharate

Reason Failed Impurities/Degradation Specifications:

Granules Pharmaceuticals Inc. NDC 70010-030-01 D-0670-2025
Class III · Low risk Ongoing

Dextroamphetamine Saccharate

Reason Failed Impurities/Degradation Specifications:

Granules Pharmaceuticals Inc. NDC 70010-029-01 D-0669-2025
Class II · Moderate risk Ongoing

Aripiprazole Tablets

Reason Superpotent drug

Ascend Laboratories, LLC D-0645-2025
Class I · High risk Ongoing

Green Lumber Natural Fuel For Men capsule

Reason Marketed without an Approved NDA/ANDA: FDA analysis found this product to contain tadalafil

Green Lumber Holdings, LLC D-0304-2026